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Abstract 
Objective: To conduct a systematic review of studies exploring potential biomarkers for 
development, course and efficacy of treatment of lymphomas in salivary glands of patients 
with Sjögren’s syndrome.  
 
Material and Methods: Eligible studies were identified through a comprehensive search of 
two databases, i.e. PubMed and EMBASE. Quality of included articles was assessed with 
the ‘Quality In Prognosis Studies’ (QUIPS) tool. The ‘CHecklist for critical Appraisal and data 
extraction for systematic Reviews of prediction Modelling Studies’ (CHARMS) was used to 
facilitate data extraction.  
 
Results: Fifty-eight studies met the inclusion criteria. Only one study assessed the 
progression of lymphoma. Moderate risk of bias was detected in ‘outcome measurement’, 
‘study participation’ and ‘study confounding’ domains. Parotid gland enlargement, mixed 
monoclonal cryoglobulins and low C4 levels represented strongest predictors of lymphoma 
development. The role of histological biomarkers, and specifically germinal centers, remains 
controversial. Clinical and methodological heterogeneity across studies precluded conduct of 
a meta-analysis.  
 
Conclusions: Specific biomarkers in combination with clinical manifestations represent 
potential candidates for advancing precision medicine approaches to lymphoma prediction in 
patients with Sjögren’s syndrome. Current focus has increasingly been on genetic and 
epigenetic markers as candidate predictors.   Predictive accuracy of key biomarker 
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Introduction 
Sjögren’s syndrome (SS) is a common rheumatic disease with an estimated prevalence of 
61 cases per 100 000 inhabitants in the general population (Qin et al., 2015). SS commonly 
affects the salivary and lacrimal glands, while the most common symptoms are sensation of 
dry mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca) (Vissink et al., 2012). 
Although exact pathogenic mechanism remains to be elucidated, the minor and major 
salivary glands are characteristically infiltrated by mononuclear lymphoid cells (Kroese et al., 
2013). Enlargement of major salivary glands, especially the parotid and submandibular 
gland, is also a common phenomenon. This enlargement is usually bilateral, may be non-
painful to slightly tender, as well as intermittent to persistent in nature. An estimated 7.5% of 
patients with SS develop malignant B-cell lymphoma during the course of their disease, 48-
75% of which is of the MALT-type (Sutcliffe et al., 1998; Theander et al., 2006).  
Translation of precision medicine into mainstream clinical care is being prioritized worldwide 
and is increasingly being advanced as the future paradigm for more effective medical 
management. Precision medicine, also coined as P4 medicine by Hood and Friend (2011), 
who characterized it as being ‘predictive’, ‘preventive’, ‘personalized’ and ‘participatory’, 
embraces a systems approach to understanding underlying disease pathophysiology 
coupled with individually- tailored health care informed by an individual’s genes, lifestyle and 
environment (Hodson, 2016). Advancement of precision medicine has remained largely in 
the increasingly-active research arena which is rapidly expanding the list of candidate 
biomarkers and definition of clinical phenotypes, with only a few advances of note in the 
clinical arena. As a recent example, a high pretreatment number of CD20+ B-cells/mm2 was 
shown to predict the responsiveness of patients with SS to rituximab treatment, therefore 











This article is protected by copyright. All rights reserved. 
Since precision medicine approaches to targeting specific molecules in biological pathways 
continues to successfully make inroads into cancer treatment and improved survival 
outcomes, research efforts have focused on defining both phenotypic characteristics and 
molecular signals that underlie emergence of glandular lymphomas that evolve in a subset of 
at-risk individuals with SS. In order to provide precision medicine to patients with SS, it is 
also of utmost importance to be able to predict not only the development and course of 
lymphoma in their salivary glands but also response to treatment. Such knowledge will allow 
health care providers to closely monitor high-risk SS patients, intervene as early as possible, 
and administer a targeted personalized treatment protocol. The growing evidence base 
continues to report on relevant biomarkers that have been extensively studied to date and 
continue to remain under investigation. In addition, meta-omics research approaches are 
rapidly expanding the scope of additional biomarkers which, in combination with clinical 
phenotypes, may be candidates for translation into the clinical arena in the foreseeable 
future. Therefore, the aim of this study was to conduct a systematic review in order to 
identify potential predictive biomarkers for development, course and efficacy of treatment of 
lymphomas in the salivary glands of patients with SS. 
 
Material and methods 
a. Literature search strategy 
A systematic literature search of two electronic databases (PubMed and EMBASE) was 
undertaken to identify publications on biomarkers and other phenotypic characteristics 
associated with identifying risk for lymphoma detected in salivary glands and course of 
lymphoma in patients with SS. To insure comprehensiveness of the search, manual review 
of citations of relevant studies was also undertaken to identify additional relevant 
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applied. According to the syntax rules of each database, key words and their combinations 
were used to identify the studies published prior to June 2018 (Table S1).  
 
b. Study eligibility 
Two observers (K.D. and A. Vis.) independently assessed titles and abstracts identified in 
the initial search. Inclusion criteria were studies examining potential biomarkers predicting 
lymphoma development or course or efficacy of lymphoma treatment in the salivary glands 
of patients with SS. Exclusion criteria which applied to title and abstract reviews included: 
case reports, case series with fewer than five cases, expert opinion publications, letters to 
the editor, review articles, studies that did not report on potential biomarkers predicting 
lymphoma development or course or treatment in the salivary glands of patients with SS, 
and congress abstracts. If the title and abstract provided only limited information, or if 
eligibility could not be readily discerned, publications then underwent full text assessment. 
The results of the assessment were compared, and any disagreement was resolved by 
consensus of the two reviewers.  
Full texts of the included titles and abstracts were independently assessed according to the 
aforementioned criteria by the same observers. Additionally, the ‘QUality In Prognosis 
Studies’ (QUIPS) tool was used to assess the risk of bias of the included studies (Hayden et 
al., 2013). This tool consists of six domains covering ‘study participation’, ‘study attrition’, 
‘prognostic factor measurement’, ‘outcome measurement’, ‘study confounding’, and 
‘statistical analysis and reporting’. After each stage of selection, inter-observer agreement 
was calculated as Cohen’s kappa and percentage of agreement. Studies written in a 
language in which the assessors were not proficient were translated into English by 
researchers fluent in both that language and English. Data extraction was performed on 
study and patient characteristics, and on the validity of biomarkers to predict lymphoma 
development and efficacy of lymphoma treatment in the salivary glands of patients with SS. 
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Modelling Studies’ (CHARMS) was used to facilitate data extraction (Moons et al, 2014). The 
reporting of this study complied with the ‘Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses’ (PRISMA) statement  (Moher et al., 2009). 
 
c. Statistical analysis 
Inter-observer agreement applying Cohen’s Kappa and absolute agreement was calculated 
with IBM Statistic9s 23 (SPSS, Chicago, Illinois, USA). Data were tabulated into a Microsoft 
Excel spreadsheet and simple descriptive analyses were performed (Microsoft Excel 2010, 
Redmond Washington, USA).  
 
Results 
1. Study identification and selection 
A total of 1,086 papers was initially identified. Search results were imported into RefWorks 
(ProQuest LLC, Ann Arbor, Michigan, USA), compiled and duplicates were removed by the 
software. The remaining papers were further scanned individually to manually remove 
undetected duplicates. After excluding duplicates, 814 papers were retrieved and underwent 
title and abstract review (Figure 1). Subsequently, 677 titles and abstracts were excluded (a 
list of all identified papers and excluded papers not presented in this paper can be requested 
from the corresponding author). Cohen’s Kappa agreement was 0.983 and the absolute 
agreement was 99.6%. Additional manual review of the literature did not identify any articles 
meeting inclusion criteria.  The full text of 137 studies was then screened. Finally, 58 studies 
were included for quality assessment (Figure 1). Cohen’s Kappa and absolute agreement at 
this stage was 0.803 and 90.4%, respectively. Manual review of citations of relevant studies 
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2. Quality assessment of studies 
Low risk of bias was observed in ‘prognostic factor measurement’, ‘study attrition’ and 
‘statistical analysis’ (84.5%, 55.3% and 50.0% of the included studies, respectively), while 
moderate risk of bias was identified in ‘outcome measures’, ‘study participation’ and ‘study 
confounding’ in 91.4%, 75.9% and 65.5% of the studies, respectively. The percentage of 
studies with high risk of bias was low, and varied across the different domains between 0-
12% of the included studies (Figure 2; Supplementary Table 2). 
 
3. Study characteristics 
In the 58 studies that were included for quality assessment, SS was diagnosed according to 
the American European Consensus Group (AECG) Criteria (Vitali et al., 2002), European 
Community Study Group (ECSG) Criteria (Vitali et al., 1993), or other criteria in 72%, 16% 
and 12%, respectively. One study used the recently published 2016 American College of 
Rheumatology-European League Against Rheumatism (ACR-EULAR) criteria (Shiboski et 
al., 2017). The source of data of the included studies was from cohort (53%), case-control 
(30%), registry (10%) or other (i.e., case series or unspecified, 7%) studies. In 44% of the 
included studies, consecutively enrolled patients were included; in 24.5% of the included 
studies participants were included only if data of interest were available. In 31.5% of the 
studies the patients’ eligibility and recruitment method was not specified. The majority of the 
studies (53%) were performed at a single institution, while 32% of the studies had multi-
center design with the number of participating centers ranging from 2 to 15.  
In total, 1,418 patients with SS and lymphoma were investigated. In 77% of studies 
lymphomas were explicitly defined as non-Hodgkin lymphoma (NHL).  Among these, 70% 
explicitly defined the NHL as B-type. In 65% of the studies, mucosa associated lymphoma 
tissue (MALT) type was described. Lymphoma type was not specified in 22% of studies. 
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ranging from 1.9 to 46.6 years. In the majority of studies (94%), the approach to lymphoma 
diagnosis was not specified nor if it was diagnosed with the same method for all patients.  
  
4. Predictive biomarkers 
i. Combination of clinical and serological biomarkers 
The majority of studies investigated the predictive value of clinical manifestations in 
combination with serological biomarkers. As shown in Table 1 and regarding the various 
clinical manifestations assessed, the following were more frequently associated with patients 
with SS who developed lymphoma: presence of parotid gland enlargement, purpura, 
peripheral nervous system involvement, splenomegaly, lymphadenopathy, Raynaud’s 
phenomenon, fibromyalgia, high EULAR Sjögren’s Syndrome Disease Activity Index 
(ESSDAI), clinical ESSDAI (clinESSDAI, i.e., ESSDAI without the biological domain), 
high/high-intermediate international prognostic index (IPI), bone marrow involvement and 
low grade fever. These clinical manifestations were typically investigated in combination with 
serological biomarkers, including presence of neutropenia, cryoglobulinemia, 
hypergammaglobulinemia, hypocomplementemia, (i.e., low C3 levels and/or low C4 levels), 
leukocytopenia, anemia, monoclonal gammopathy, thrombocytopenia, anti-Ro/SSA or/and 
anti-La/SSB, rheumatoid factor (RF) positivity, elevated lactic dehydrogenase (LDH) and 
CD4+ lymphocytopenia. Table 1 summarizes key findings among studies assessing a 
combination of clinical and serological biomarkers. Parotid gland enlargement in combination 
with low C4 levels was found to be predictive of lymphoma development in approximately 
half  of the studies (Fragioudaki et al., 2016; Ioannidis et al., 2002; Ismail et al., 2013; 
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ii. Serological biomarkers 
The predictive value of serological biomarkers was the second most popular studied model 
with 11 studies retrieved. Serological or laboratory measures under consideration as 
potential candidate biomarkers associated with emergence of lymphoma in salivary glands 
among patients with SS included: presence of anemia, anti-SSA and/or anti-SSB positivity, 
cryoglobulinemia, high levels of Fms-like tyrosine kinase 3 ligand, hypergammaglobulinemia, 
leukopenia, hypocomplementemia, i.e. low C3 levels and/or low C4 levels, and monoclonal 
gammopathy (Table 2). Hypocomplementemia and/or cryoglobulinemia, were found to be 
predictive of lymphoma development in all relevant studies (Brito-Zeron et al., 2017, De Vita 
et al., 2012; Kimman et al., 2018; Martel et al., 2011; Quartuccio et al., 2015; Quartuccio et 
al., 2014; Ramos-Casals et al., 2005; Ramos-Casals et al., 2008; Retamozo et al., 2016; 
Tzioufas et al., 1996).  
 
iii. Histological characteristics 
One of the most common yet controversial histologic risk factors assessed regarding 
lymphoma prediction was the presence of germinal centers (GC). Several studies concluded 
that the presence of GC in diagnostic biopsies was not predictive of MALT lymphoma 
development in SS patients (Kapsogeorgou et al., 2013; Johnsen et al., 2014; Haacke et al., 
2017), while others showed opposite results (Bombardieri et al., 2007; Theander et al., 2011; 
Sene et al., 2018). Lymphocytic focus score (LFS) ≥3, i.e. ≥3 aggregates of 50 or more 
lymphocytes/4 mm2 of glandular tissue, was found to be able to identify SS patients with an 
increased risk for lymphoma development (Risselada et al., 2014; Risselda et al., 2015; 
Carrubi et al., 2015). Similarly, elevated FcRL4+ expression (Haacke et al., 2017) and 
pSTAT-3 expression (Ciccia et al., 2015) were reported in diagnostic biopsies of patients 
who developed MALT lymphoma, while weak or absent A20 staining was observed in the 
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suggested that lymphoma development might be related to suppression of apoptotic death 
by Bcl-2, while Ussmuller et al. (2002) support that myoepithelial sialoadenitis, defined as 
benign lymphoepithelial lesions, were highly relevant in predicting lymphoma development. 
 
iv. Genetics 
Fragkioudaki et al. (2017) investigated the prevalence of specific polymorphisms in the 
methylene tetrahydofolate reductase (MTHFR) gene and observed an increased frequency 
of c. 677C > T TT genotype and T allele, as well as reduced prevalence of the c. 1298A > C 
C allele in the subset of patients with SS who did not develop MALT lymphoma compared to 
controls and patients without NHL. Five single nucleotide polymorphisms (SNPs) of the B 
cell activating factor (BAFF) gene (rs1224141, rs12583006, rs9514828, rs1041569 and 
rs9514827) were evaluated in the study of Nezos et al. (2013), where patients with SS at 
high risk of developing lymphoma were characterized by higher frequency of the minor T 
allele of the rs9514828 and lower frequencies of the AA genotype of the rs12583006 
polymorphism. The rs2230926 exonic variant of the ubiquitin-editing enzyme TNF AIP3 that 
regulates nuclear factor kappa B (NF-kB), was associated with an increased risk for 
lymphoma in the study of Nocturne et al. (2013). NF-kB receptor upregulation has been 
associated with lymphoid tumorogenesis. TNF AIP3 in combination with A20 down-regulates 
NF-kB activity and acts as a tumor suppressor. 
Significantly lower levels of miR200b-5p, a miRNA which regulates expression of 
autoantibodies directed to intracellular autoantigens, La/SSB, were characterized in SS 
patients with MALT lymphoma compared with those without (p<0.05) (Gourzi et al., 2015). 
Similarly, in the study of Kapsogeorgou et al. (2018), miR200b-5p was significantly 
downregulated in patients with SS who would develop or had NHL, and was able to 
discriminate this subset (p<0.0001) from those without lymphoma or those with non-SS 
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patients who would develop NHL. Regarding methylating enzymes, SS patients with 
lymphoma were characterized by an intense decrease of methyl CpG-binding protein 2 
(MeCP2) and DNA methyltransferase (DNMT) 3B (Mavragani et al., 2018). Recently, 
Vakrakou et al. (2018) reported that NLRP3 inflammasome activation and the widespread 
DNA accumulations in tissues, contributed a key role in NHL development in patients with 
SS.  
 
v. Chemokines as biomarkers 
Barone et al. (2008) reported that CXCL12 was principally detected in infiltrated ducts and 
malignant B-cells in the salivary glands of patients with SS. Additionally, CXCL12 levels 
were increased in MALT lymphomas and isolated tumor cells, suggesting the direct 
involvement of CXCL12 in the organization of ectopic reactive lymphoid tissue and its 
association with the malignant B-cell component and regulation of malignant B-cell survival. 
Similarly, Nocturne et al. (2015) showed that patients with SS who developed lymphoma had 
higher levels of serum CXCL13 (a chemokine promoting B-cell chemotaxis that promotes 
ectopic, B-cell rich, lymphoid tissue formation) than patients with no lymphoma  (193.65 
pg/ml [IQR=101.71–501.33] vs 108.31 pg/ml [IQR 59.95–197.25]; p=0.006) and also tended 
to have a higher level of serum CCL11 (139.44 pg/ml [IQR=82.91–177.73] vs 106.66 pg/ml 
[IQR 70.12–147.19]; p=0.056).  
 
vi. Salivary biomarkers 
a. Salivary proteins 
Anti-coffilin-1, anti-alpha enolase, anti-Rho GDP-dissociation inhibitor 2 (RGI2) were all 
found to be over-expressed in patients with SS who developed MALT lymphoma compared 
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three auto-antibodies resulted in an AUC value of 0.86 with a 75% sensitivity and 94% 
specificity in distinguishing SS patients with MALT lymphoma from those without  MALT (Cui 
et al., 2017).  
b. Parotid scintigraphy 
SS patients with class 4 involvement in the salivary glands, i.e. with severe involvement, 
showing no active concentration of the technetium 99 tracer, were found to have a higher 
rate of lymphoma development. Additionally, adjusted multivariate Cox regression analysis 
showed a hazard ratio (HR) of 10.51 (p=0.002) and Kaplan–Meier analysis showed a log-
rank of 0.0005 (Ramos-Casals et al., 2010). 
c. Ultrasound of the major salivary glands (SGUS) 
SGUS scores of 2 or 3 (Hocevar et al., 2005) were associated with markers of lymphoma. 
Specifically, GC-like structures in the original salivary gland biopsy findings, CD4 T-cell 
lymphopenia, and reduced number of memory B-cells in the circulation, immunoglobulin 
oligo- or monoclonality in serum, the presence of salivary gland swelling, and purpura and 
skin vasculitis were more frequently observed in patients with SS with several or numerous 
or confluent rounded hypoechoic lesions compared with patients with a normal SGUS 
(p<0.05) (Theander and Mandl, 2014).  
 
vii. Microbiological biomarkers 
Only two studies assessed the potential role of microbiological biomarkers, e.g. viral or 
bacterial, in the prediction of lymphoma in SS patients. Higher prevalence of Chlamydophila 
psittaci was reported in patients with SS with MALT lymphoma, compared to those with 
myoepithelial sialoadenitis or no lymphoproliferative disorder (p=0.02) (Fabris et al., 2014). 
Hirose et al. (1999) reported no association between presence of Epstein-Barr virus and 
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5. Predictive scoring systems for development of lymphoma in salivary glands of 
patients with SS  
A few studies (n=5) investigated possible predictive scores for lymphoma development by 
meaningfully combining several risk factors. Table 3 presents a comprehensive overview of 
these studies. The presence of hypocomplementemia, and specifically of low C4 levels, was 
a risk factor consistently included in all scoring systems (Baimpa et al., 2009 ; Fragioudaki et 
al., 2016 ; Ioannidis et al., 2002 ; Quartuccio et al., 2014; Solans-Laque et al., 2011).  
 
Discussion 
In the context of precision medicine, discovery and validation of quantifiable biomarkers 
defined by omics approaches, in combination with clinical phenotypic definitions associated 
with disease presentation, is necessary to aid in risk prediction, diagnosis, treatment 
outcome prediction and assessment of disease progression. Regarding SS, it is of high 
importance to not only predict which patients with SS are at risk of developing lymphoma, 
but also to predict site of emergence, since lymphomas could rise either in the salivary 
glands or stomach or lymph nodes or thymus. This systematic review sought to define the 
current state of the science relative to application of precision medicine approaches for 
identification, outcome prediction and management of patients with SS who are at risk for 
lymphoma emergence in the salivary glands, since lymphomas of the salivary glands occur 
with the highest frequency (Dong et al., 2013), representing the vast majority of emergent 
lymphomas observed in SS.   
Lymphoma in salivary glands of patients with SS can manifest as completely indolent, but 
can also be accompanied by severe disease activity, i.e. high ESSDAI, with local or more 
extensive dissemination. Consequently, treatment may vary from watchful waiting to more 
therapeutically complex approaches, such as treatment with rituximab, cyclophosphamide 
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medicine in the context of SS, is development of the capacity to predict the development of a 
lymphoma in patients with SS and prognosis associated with the course of lymphoma and 
efficacy of treatment. Identification of appropriate biomarkers would advance achievement of 
these capabilities in the clinical arena. Biomarkers are defined as characteristics that can be 
objectively measured and evaluated as indicators of normal biological or pathogenic 
processes, or as indicators of pharmacologic responses to therapeutic interventions 
(Biomarkers Definitions Working Group, 2001). T 
This systematic review delineated 57 different biomarkers in 58 studies as risk factors of 
lymphoma development in the salivary glands of patients with SS. These could then be 
further classified in: clinical and histological manifestations, serological or otherwise 
quantifiable through analysis in a laboratory setting, and by omics approaches including 
definition of genetic risks, proteomic (expression of chemokines), salivary (proteomic or 
metabolomic) and microbiological analyses to define potential disease-associated 
pathogens. The current state of the art suggests that clinical manifestations in combination 
with serological biomarkers currently represent the most frequently assessed variables in the 
clinical setting to inform delivery of personalized care, likely because of their ease of 
applicability. This systematic review determined that the majority of studies focused on 
identifying biomarkers that predict lymphoma development, while only one study assessed 
biomarkers predicting the progression of lymphoma (Papageorgiou et al., 2015).  
Conclusions of available studies regarding histological biomarkers were inconclusive. 
Studies with central focus on GCs reported contradictory results (Kapsogeorgou et al., 2013; 
Johnsen et al., 2014; Haacke et al., 2017; Bombardieri et al., 2007; Theander et al., 2011; 
Sene et al., 2018). This dichotomy could be principally attributed to the considerable variety 
in histological definitions of GC used in the various studies, as well as to the absence of 
consensus guidelines to standardize their assessment (Delli et al., 2016). Biomarkers could 
aid in histological definition. Specifically, activation-induced deaminase, an enzyme essential 
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a marker of follicular dendritic cells (Hillen et al., 2016), and Bcl-6; a transcription factor 
expressed at high levels by GC B-cells (Delli et al., 2017), have been proposed for definition 
and identification of GCs. Notably, Nakshbandi et al. (2019) recently showed that Bcl-6 is the 
most appropriate marker for identification of GCs in salivary gland biopsies of SS patients. In 
contrast to hematoxylin-eosin stain and CD21 immunohistochemistry, Bcl-6 supports 
unequivocal identification of GCs. 
In one-third of the studies, patients’ eligibility and recruitment method was not specified, 
raising concerns about possible selection bias. Additionally, in one quarter of the studies, 
patients were included only when data of interest were available and no additional analysis 
was performed to identify the impact of the missing data. Thus, it is unclear in most of the 
studies whether data were missing completely at random, at random or not at random. This 
shortcoming may have resulted in unrepresentative study populations and thus may cause 
bias in the validity of the biomarkers under investigation (Donders et al., 2006).   
Lastly, the predictive value of a biomarker, as investigated in a particular study, is applicable 
to the timeframe in which the recruited patients were followed (Betensky, 2015). In 
approximately 50% of studies, the exact follow-up period of the patients was not mentioned 
and the onset of lymphoma in the natural history of SS was not precisely defined. Therefore, 
it remains unclear how the predictive biomarker should be used in daily practice (Rector et 
al., 2012).      
 
Strengths and limitations   
Strengths of the current systematic review were the detailed literature search on the two 
prevailing databases, i.e. PubMed and EMBASE, without time and language restrictions, 
assessment of study eligibility by two reviewers, good inter-observer agreement, and 
application of the QUIPS tool to assess the quality of the studies and utilization of the 
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outcomes was the high clinical and methodological heterogeneity of the included studies. 
Specifically, a variation in study populations, study designs, and outcome measures were 
identified which precluded meta-analysis. Lastly, the fact that studies included often patients 
with a mix of both salivary and extra-salivary gland lymphomas, cannot exclude the 
possibility that (some of) the observed  predictive biomarkers are not exclusively applicable 
to salivary lymphomas, but could also be relevant in case of extra-salivary gland lymphomas. 
Since studies were included only if  they reported on ≥5 patients with lymphoma in the 
salivary glands, the generalizability of the conclusions to the salivary lymphomas is, 
however, ensured.  
 
Implications and future research 
Future studies should comply with the QUIPS and CHARMS guidelines in order to ensure 
high predictive quality. Particular attention should be paid to the QUIPS domains where 
moderate risk of bias is observed, viz.: 
 1) the study sample should adequately represent the SS population, thus a 
consecutive or random sample of SS patients should be used; a case control design 
and inappropriate exclusion of patients should be avoided;  
2) lymphoma should be diagnosed in a similar manner for all participants, the method 
used to diagnose lymphoma should be clearly defined and lymphoma should be 
assessed without knowledge of the candidate predictors;  
3) important confounders should be accounted and appropriately measured;  
4) researchers should be encouraged to develop predictive models, applying logistic 
regression analysis, Cox survival analysis, neural networks, or by application of 
machine learning techniques, whose performance and evaluation should be properly 
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neural network analyses previously hidden formation could potentially be discovered 
in complex diseases like SS.   
The aforementioned features should be stated clearly by authors to avoid potential 
misinterpretation or poor evaluability. There is a need for an international prospective 
registry, where patients newly-diagnosed with SS according to the ACR-EULAR criteria are 
included with subsequent longitudinal follow-up, and collection of structured data at 
specifically defined time-points.  
 
Conclusion 
Rapidly expanding clinical manifestations to support definition of phenotypes and biomarkers 
with the potential to predict lymphoma in the salivary glands of patients with SS continue to 
contribute to realization of a precision medicine approach to lymphoma risk prediction in SS. 
The most commonly used predictive biomarkers and clinical manifestations currently defined 
for use in clinical practice is documentation of low C4 levels and cryoglobulins in 
combination with the presence of parotid gland enlargement. The role of histological 
phenotypes and definition of informative biomarkers remain controversial. Increased 
research activity was detected with focus on defining specific genetic polymorphisms and 
useful clinical epigenetic markers. However, due to the high heterogeneity of studies, further 
research is required to elucidate the predictive value and utility of these biomarkers in a 
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Tables:  
Table 1: Overview of studies assessing the predictive value of clinical manifestations in combination with serological biomarkers.   
Authors, year  Participants Biomarker(s) Conclusion 
Baimpa et al.,  
2009 
 536 SS  Cryoglobulinemia  
 Low C4 levels  
 Lymphadenopathy  
 Neutropenia 
 Splenomegaly  
 Neutropenia (HR, 8.97; 95% CI, 1.10-73.30; 
p=0.04), cryoglobulinemia (HR, 2.91; 95% CI, 1.15-
6.44; p=0.008), splenomegaly (HR, 3.97; 95% CI, 
1.49-10.62; p=0.006), lymphadenopathy (HR, 2.62; 
95% CI, 1.15-5.94; p=0.021), and low C4 levels 
(HR, 3.31; 95% CI, 1.35-8.12; p=0.009) were 
independent risk factors for the development of 
lymphoma. 
 Patients carrying any of these factors had a more 
than 5.4-fold increased risk of NHL compared to 
patients with no risk factors.  
Baldini et al.,  
2013 





 81 sicca SSc 




 Parotid enlargement 
Purpura 
 Peripheral nervous system 
involvement 
 Parotid enlargement, purpura, peripheral nervous 
system involvement, hypergammaglobulinaemia 
and leukocytopenia were significant risk factors for 




 381 SS without 
NHL 
 73 SS with MALT 
 19 SS with (non-
MALT) NHL 
 Anti-Ro/SS  
 Anti-La/SSB positivity  
 Low C4 levels  
 Lymphadenopathy 
 Monoclonal gammopathy 
 Parotid enlargement 
 Raynaud  phenomenon 
 Salivary gland enlargement (OR 4.3, 95% 2.0–9.1), 
lymphadenopathy (OR 4.2, 95% 1.8–9.9), Raynaud  
phenomenon (OR 2.3, 95% 1.0–5.2), anti-Ro/SS 
or/and anti-La/SSB positivity (OR 3.8, 95% 1.1–
13.4), RF positivity (OR 3.7, 95% 1.4–10.0), 
monoclonal gammopathy (OR 3.2, 95% 1.0–9.8), 
and C4 hypocomplementemia (OR 3.0, 95% 1.3–
6.8) were identified as independent predictors for 
NHL development. 










This article is protected by copyright. All rights reserved. 
development in the presence of: 
a. all 7 risk factors were 210.0 (10.0–4412.9), 
p<0.0001 compared to those with 2 or less risk 
factors.  
b. 3 to 6 risk factors were 16.6 (6.5–42.5), p<0.05 
in comparison with patients presenting with 2 or 




 723 SS patients  Low C4 levels 
 Parotid enlargement   
 Purpura (palpable) 
 Parotid enlargement (HR 5.21, 95% CI 1.76–15.4; 
p=0.003), palpable purpura (HR 4.16, 95% CI 1.65–
10.5; p=0.002), and low C4 levels (HR 2.40, 95% CI 
0.99–5.83; p=0.052) were independent predictors of 
lymphoma or other lymphoproliferative disease.  
 Patients with at least 1 of these 3 adverse risk 
factors at baseline had a 9.08-fold higher risk of 
developing lymphoma or other lymphoproliferative 
disease in the future (95% CI 2.13–38.7) than those 
who did not. 
Ismail et al.,  
2013 
 PART I: 8 SS 
patients with B-cell 
NHL 
 
 PART II: - 50 SS 
                    - 25 
healthy        
 Cryoglobulin positivity  
 Fibromyalgia 
 High lactic dehydrogenase 
(LDH)  
 Low C3 and C4 levels  
 Lymphadenopathy  
 Lymphocytopenia (CD4+) 
 Parotid enlargement  
 Purpura  
 Significant difference was observed between SS 
patients with lymphoma and those without 
lymphoma in the prevalence of parotid enlargement, 
lymphadenopathy, purpura, fibromyalgia, low C3 
and C4, cryoglobulin positivity, and high lactic 




 248 SS   Anti-SSA 
 Cryoglobulenaemia 
 Hypergammaglobulenaemia  
 Leukopenia,  
 Neurological involvement  
 Parotid enlargement 
 Significant difference between SS patients with 
lymphoma and those without lymphoma in the 
prevalence of parotid enlargement, vasculitis, 
splenomegaly, neurological involvement, 
hypergammaglobulenemia, cryoglobulenemia, 
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 RF (high titre) 
 Splenomegaly  
 Vasculitis  
correlated with the occurrence of lymphoma 
(p<0.05).  
Nocturne et 




 PART II:  
- 77 SS patients 
with lymphoma 
- 154 SS patients 
without lymphoma 
 
 ClinESSDAI score ≥5 
 Cryoglobulinemia 
 ESSDAI 
 low C4 level 
 lymphopenia 
 Parotid enlargement 
 RF 
 Model 1: independently associated with 
development of lymphoma in patients with primary 
SS were salivary gland enlargement (OR 3.48 95% 
CI 1.50–8.07; p=0.0037), presence of RF (OR 3.04 
1. 95%CI 33–6.93; p=0.0083), presence of 
cryoglobulinemia (OR 3.68 95% CI 1.38–9.83; 
p=0.0093), low C4 level (OR 3.16 95%CI 1.32–
7.55; p=0.0098), and lymphopenia (OR 5.65 95% 
CI 2.46–12.99; p=0.0001)  
 Model 2: independently associated with 
development of lymphoma were ESSDAI (OR 3.84, 
95% CI 1.98–7.43; p=0.0001) and RF (OR 3.40 
[95% CI 1.71–6.75; =0.0005)  
 Model 3: independently associated with the 
development of lymphoma were RF positivity (OR 
4.01, 95% CI 1.78–9.00; p=0.0008), presence of 
cryoglobulinemia (OR 4.07, 95% CI 1.65–10.02; 
p=0.0023), low C4 (OR 2.33 95% CI 1.05–5.15; 
p=0.0372) and ClinESSDAI score ≥5 (OR 3.53 95% 
CI 1.63–7.65; p=0.0014) were independently 
associated with the development of lymphoma.   
Papageorgiou 
et al., 2015 
 77 SS patients with 
lymphoma 
 Total ESSDAI score >10 
 International prognostic 
index (IPI)  
 SS patients with lymphoma and high disease 
activity (total ESSDAI score >10) had greater risk to 
experience a death (OR=5.241, 95% CI: 1.034–
26.568, p=0.045) or an event, i.e. lymphoma 
relapse, treatment failure, disease progression, 
histological transformation, (OR=4.317, 95% CI: 
1.146–9.699, p=0.008), and significantly worse 
event free survival (EFS) and overall survival 
compared to SS patients with lymphoma and low 
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HR=4.541, 95% CI: 1.772–11.637; OS: log-rank 
p=0.011, HR=5.946, 95% CI: 1.259–28.077).  
 Improvement in the total ESSDAI score six months 
after completion of first-line treatment (delta 
ESSDAI) among patients who had experienced an 
event (mean delta ESSDAI±SD: 4.59±1.68) was 
significantly less than that seen in event-free 
patients (mean delta ESSDAI±SD: 6.87±3.33) 
(p=0.005). 
 In high/high-intermediate international prognostic 
index (IPI) group of patients, the risk of death was 
13.867 times greater (95% CI: 2.656–72.387, 
p=0.002) and the risk of event was 12.589 times 
greater (95% CI: 3.911–40.526, p<0.001) compared 
to low/low-intermediate IPI risk group. SS-
associated NHL patients with bone marrow 
involvement at lymphoma diagnosis had 3.333 
times greater risk (95% CI: 1.146–9.699, p=0.027) 
to experience an event during follow-up. 
Risselada et 
al., 2013 
 195 SS patients  ESSDAI  
 Low C4 levels 
 Parotid gland enlargement 
 Parotid gland enlargement (OR 2.84) and low C4 
(OR 7.71) were observed more commonly in SS 
patients developing NHL.  
 Presence of IgM kappa clonal components was 
associated with lymphoma in 64% of cases.  
 Disease activity (ESSDAI)/severity (cumulative 
ESSDAI and extraglandular manifestation) scores 
at first visit could not predict lymphoma 
development, nor was the pSS disease course 
significantly worse in patients with NHL.  
Solans-Laque 
et al., 2011 
 115 SS patients  Anemia  
 Hypergammaglobulinemia 
 Leukopenia  
 Low C3 levels  
 Unvariate Cox regression analysis identified parotid 
enlargement (HR 6.75, 95% CI 1.89-23.99), 
palpable purpura (HR 8.04, 95% CI 2.33-27.67), 
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 Low C4 levels  
 Parotid enlargement  
 Purpura (palpable) 
(HR 8.70, 95% CI 2.38-31.82), lymphocytopenia 
(HR 16.47, 95% CI 3.45-78.76), 
hypergammaglobulinemia (HR 4.06, 95% CI 1.06-
15.58), low C4 levels (HR 39.70, 95% CI 8.85- 
126.18), and low C3 levels (HR 36.65, 95% CI 
10.65- 116.12) at the time of pSS diagnosis, as 
significant predictors of lymphoproliferative disease.  
 The multivariate analysis identified only 
lymphocytopenia and low C3/C4 levels at pSS 
diagnosis as independent predictors of lymphoma. 
Voulgarelis et 
al., 1999 
 33 SS patients with 
NHL 
 Anemia  
 Low grade fever  
 Lymphadenopathy  
 Lymphopenia  
 Peripheral nerve 
involvement  
 Vasculitis  
 Lymphadenopathy (65.6%), skin vasculitis (33.3%), 
peripheral nerve involvement (24.2%), low grade 
fever (25%), anemia (48.1%) and lymphopenia 
(78.6%) were significantly  more  frequently 
observed in SS patients who developed a 
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Table 2: Overview of studies assessing the predictive role of serological biomarkers alone.  
Authors, year Participants Biomarker(s) Conclusion 
Brito-Zeron et 
al., 2017 
 1300 SS patients  Anemia 
 Cryoglobulinemia 
 Hypergammaglobulenemia 
 Low C3 levels 
 Low C4 levels 
 For MALT lymphomas, baseline 
prognostic factors associated with B-
cell MALT lymphomas were 
cryoglobulins (HR 6.32; p < 0.001) and 
low C3 levels (HR 3.25; p=0.010) 
 For B-cell non- MALT lymphomas, the 
prognostic factors included anemia 
(HR 2.58; p=0.047), monoclonal 
gammopathy (HR 3.45; p=0.024), 
cryoglobulins (HR 3.34; p=0.028), and 
low C4 levels (HR 3.83; p=0.014). 
De Vita et al., 
2012 
 41 SS patients with parotid 
myoepithelial sialadenitis or 
B-cell NHL 
 
 Cryoglobulinemia  
 
 Significantly higher prevalence of 
cryoglobulinemia in SS patients with 
lymphoma (72.2%) than in SS patients 
with parotid myoepithelial sialadenitis 
(72.2% vs 30.4%, p=0.01). 
Kimman et al., 
2018 




 Low C3 levels 
 Monoclonal bands on protein 
electrophoresis 
 Hypocomplementemia 
 Cryoglobulins were significantly higher 
in lymphoma patients compared to 
non-lymphoma patients (121 ± 250 
versus 8 ± 24.9 mg/L for IgG; 231 ± 
422 versus13 ± 30 mg/L for IgM; 10 ± 
20 versus 1 ± 4 mg/L for IgA in the 
cryoprecipitate).  
 Cryoglobulin levels were significantly 
more increasing (p-values for 
IgG=0.0007; for IgM=0.0123; and for 
IgA in the cryoprecipitate <0.0001) in 
the time period before the lymphoma 
diagnosis in lymphoma patients 
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 Low C3 (OR 13.9) or C4 (OR 7.1) 
levels, a decreasing total complement 
activity (OR 6.6), decreasing 
gammaglobulins (OR 13.4), a 
persistent detection of monoclonal 
bands (OR 14.6) on protein 
electrophoresis, a low or decreasing 
serum IgG (OR 18), and decreasing 
IgM-serum levels (OR 17.7) were 
significantly associated with 
lymphoma. 
Martel et al., 
2011 
 445 SS patients  Cryoglobulinemia  
 
 9% of SS patients with 
cryoglobulinemia vs 3% of SS patients 




 548 SS patients  Anti-SSA 
 Anti-SSB 
 Positive histology 
 SS patients with a positive histology 
and SSA/SSB positivity developed 
lymphoma more frequently compared 
to the ones with only positive histology 




 40 SS patients with NHL 
 17 SS patients with 
cryoglobulinemic vasculitis 
 180 SS patients with salivary 
gland swelling 






 Low C4 
 
 Positive serum cryoglobulins [relative-
risk ratio (RRR) 6.8, 95% CI 2.1e22.1], 
low C4 (RRR 8.3, 95% CI 3.6-19.2), 
anti-La (RRR 5.2, 95% CI 2.3-11.9), 
and leukopenia (RRR 3.3, 95% CI 1.5-
7.05) were the selected variables, by 
multinomial logistic analyses, that 
distinguished SS patients with NHL 
from control group.  
 A score 2 (i.e., the positivity of at least 
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lymphoma of 71.8% (CI 55.1-85.0) and 
specificity of 79.0% (CI 72.1-84.9).  
Ramos-Casals 
et al., 2005 
 336 patients with SS  
 
 Low C3 levels 
 Low C4 levels 
 SS patients with low C4 levels showed 
a higher prevalence of lymphoma (10 
vs 2%, p=0.013);  
 SS patients with low C3 levels showed 
a higher prevalence of lymphoma (10 
vs 2%, p=0.017). 
Ramos-Casals 
et al., 2008 
 1010 patients with SS   Hypocomplemetemia   SS patients with hypocomplemetemia 
had a higher frequency of lymphoma 
(p=0.01). 
Retamozo et al., 
2016 
 515 patients with SS   Cryoglobulinemia 
 Vasculitis (cryoglobulinemic) 
 
 Compared with patients without 
cryoglobulins, patients with 
cryoglobulins who fulfilled [hazard ratio 
(HR)=7.47, 95% CI: 3.38, 16.53] and 
did not fulfil (HR=2.56, 95% CI: 1.03, 
6.35) cryoglobulinemic vasculitis 
criteria both showed a higher risk of B-
cell lymphoma in the univariate 
analysis, but not in the multivariate 
models. 
Tobon et al., 
2013 
 369 patients with SS 
 50 healthy controls 
 Fms-like tyrosine kinase 3 
ligand 
 Higher levels of Fms-like tyrosine 
kinase 3 ligand were significantly 
associated with a history of lymphoma 
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Tzioufas et al., 
1996 
 103 patients with SS  Cryoglobulinemia 
 
 Cryoglobulinemia was found as the 
predominant factor (r=0.421, 
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Table 3: Scoring systems for predicting lymphoma development in the salivary glands of patients with SS.  
Authors, year Risk factors Prognostic classification Probability or risk of developing lymphoma 
per group 
Baimpa et al., 
2009 
1. Cryoglobulinemia 
2. Low C4 levels 
3. Neutropenia  
4. Splenomegly  
Group A: Low risk if presence of 0 risk 
factors  
Group B: High risk if presence of ≥1 
risk factors 
Group A: 3.6% probability 
Group B: 20.6% probability 
Fragioudaki et al., 
2016 
1. Anti-Ro/SS  
2. Anti-La/SSB positivity  
3. Low C4 levels  
4. Lymphadenopathy 
5. Monoclonal gammopathy 
6. Parotid enlargement 
7. Raynaud’s  phenomenon 
Group A: presence of ≤2 risk factors 
Group B: presence of 3-6 risk factors 
Group C: presence of all 7 risk factors 
Group A: 3.8% probability 
Group B: 39.9% probability 
Group C: 100% probability 
Ioannidis et al., 
2002 
1. Low C4 levels 
2. Palpable purpura  
3. Parotid enlargement  
Group A: Low risk if  presence of 0 
risk factors  
Group B: High risk if presence of ≥1 
risk factors 
Group A: reference group  
Group B: 9.08-fold higher risk than Group A 




3. Leukopenia   
4. Low C4 levels 
Group A: Presence of <2 risk factors 
Group B: presence of ≥2 risk factors 
Group A: reference group 





Group A: Low risk if  presence of 0 
risk factors  
Group B: High risk if presence of ≥ 1 
risk factors 
Group A: reference group 
Group B: significantly higher risk than Group A 
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